• Modular Learning
  • Resource Database
  • Offerings
    • Partnership Program
    • Seed Fund
    • Modular Learning
    • Resource Database
  • DRIVEN Companies
    DRIVEN Accelerator HubDRIVEN Accelerator Hub
    • Modular Learning
    • Resource Database
    • Offerings
      • Partnership Program
      • Seed Fund
      • Modular Learning
      • Resource Database
    • DRIVEN Companies

      Modular Learning: Operations

      • Home
      • Modular Learning
      • Operations
      Modular LearningOperations
      • Who is the Patient? 4

        • Section1.1
          Introduction
        • Section1.2
          Precision/Personalization, Segmentation, and Incidence/Prevalence
        • Section1.3
          Patient Journey
        • Section1.4
          Expansion/Secondary Indications
      • Standard of Care & Competition 4

        • Section2.1
          Introduction
        • Section2.2
          Unmet Need, Safety, Efficacy, Compliance, Costs
        • Section2.3
          Development Pipeline Analysis/Competitive Intelligence
        • Section2.4
          Competition in Therapeutics (5 forces)
      • Business Model 4

        • Section3.1
          Introduction
        • Section3.2
          Product, Platform or Service
        • Section3.3
          Mission, Vision, Strategy, Tactics, Operations
        • Section3.4
          Who is the Customer?
      • Regulatory 4

        • Section4.1
          Introduction
        • Section4.2
          FDA Introduction
        • Section4.3
          FDA Guidelines
        • Section4.4
          Selecting FDA Consultants
      • Exit/End Goal 4

        • Section5.1
          Introduction
        • Section5.2
          Trade Sales
        • Section5.3
          Sales
        • Section5.4
          Partnerships

        Selecting FDA Consultants

        Introduction

        There’s a lot of knowledge in the world of therapeutics development. While regulatory processes are meant to be entirely transparent, and an incredible amount of information is freely available online, regulatory is still both highly complex, and highly impactful to your business. Specialization and importance often mean consultants, especially for smaller companies that can’t afford to hire regulatory experts.

        What

        The ideal consultant isn’t one consultant, because your product is multifaceted. Consultants should have copious experience with(in) FDA, in the indication and modality in question. A single expert is unlikely to be able to be sufficiently deep in all aspects of 10 preclinical and clinical development. Determine where your risks are (e.g. CMC and clinical design), then ensure that your consultants can provide first-hand guidance.

        When

        We would suggest a few hours early in the development process to check your assumptions, then whenever you have serious regulatory questions, and whenever you’re preparing for a meeting with FDA.

        Why

        Getting positive feedback from FDA is a value driver for your business. Getting negative feedback from FDA has been the end of many businesses. Getting it right is therefore paramount!

        Learning Goals

        What to look for in your regulatory team.

         

        Prev FDA Guidelines
        Next Introduction

        driven logo inverted web

        DRIVEN Accelerator Hub   .   info@drivenacceleratorhub.com   .   NIGMS UT2GM13017

        Founded By

        © 2021 DRIVEN Accelerator Hub. All rights reserved.

        Website by RYCO

        Modal title

        Message modal